Prostate tissue, whether benign or malignant, is heavily dependent on androgen receptor
(AR) signaling for growth and proliferation. Androgen deprivation therapy has been standard …

Enzalutamide, a second-generation small-molecule inhibitor of the androgen receptor (AR),
has been approved for patients who failed with androgen deprivation therapy and have …

Recent advances in understanding the mechanisms underlying the development and
progression of castration resistant prostate cancer from androgen-sensitive prostate cancer …

Prostate cancer (PCa) is the most common malignancy, and the third leading cancer-related
cause of death among men of the Western world. Upon PCa progression into metastatic …

The androgen receptor drives the growth of metastatic castration-resistant prostate cancer.
This has led to the development of multiple novel drugs targeting this hormone-regulated …

To alleviate metastatic castration-resistant prostate cancer (mCRPC), enzalutamide, a non-
steroidal antiandrogen, is employed. Following androgen deprivation therapy or anti …

Background: Despite the progress and innovation in chemo-and immunotherapies,
androgen deprivation therapy remains the standard treatment of metastatic prostate cancer …

Introduction: In patients with metastatic prostate cancer (PCa), castration is the standard first-
line therapy. However, all patients eventually develop castration-recurrent PCa (CRPC). In …

Enzalutamide is a nonsteroidal antiandrogen for the treatment of metastatic castration-
resistant prostate cancer (mCRPC) both before and after chemotherapy. Enzalutamide is …

Introduction: Enzalutamide is an oral androgen receptor (AR) signaling inhibitor that was
specifically engineered to overcome castration-resistant prostate cancer (CRPC) harboring …